| Quarterly Financials | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 810 | 810 | 959 | 932 | 941 | 979 | 1,004 | 1,132 | 1,202 | 1,267 | 1,294 | 1,419 | 1,451 | 1,501 | 1,498 | 1,588 | 1,574 | 1,525 | 1,558 |
| Expenses | 743 | 745 | 859 | 863 | 872 | 914 | 941 | 1,061 | 1,119 | 1,171 | 1,213 | 1,324 | 1,350 | 1,385 | 1,395 | 1,452 | 1,429 | 1,373 | 1,412 |
| EBITDA | 67 | 65 | 101 | 69 | 69 | 65 | 63 | 71 | 83 | 95 | 81 | 96 | 102 | 116 | 103 | 136 | 145 | 152 | 146 |
| Operating Profit % | 7 % | 7 % | 10 % | 7 % | 7 % | 5 % | 5 % | 5 % | 6 % | 7 % | 6 % | 6 % | 6 % | 7 % | 6 % | 8 % | 8 % | 9 % | 8 % |
| Depreciation | 22 | 24 | 27 | 28 | 31 | 34 | 38 | 42 | 46 | 56 | 52 | 56 | 57 | 59 | 60 | 63 | 63 | 64 | 66 |
| Interest | 13 | 15 | 15 | 16 | 17 | 19 | 20 | 20 | 21 | 22 | 23 | 24 | 25 | 25 | 25 | 25 | 26 | 27 | 27 |
| Profit Before Tax | 32 | 26 | 58 | 25 | 22 | 13 | 5 | 9 | 16 | 17 | 5 | 16 | 20 | 32 | 18 | 48 | 57 | 61 | 53 |
| Tax | 9 | 8 | 12 | 5 | 5 | 1 | 1 | 2 | 3 | -9 | 1 | 2 | 6 | -2 | 4 | 9 | 11 | 10 | 10 |
| Net Profit | 23 | 18 | 46 | 20 | 17 | 11 | 4 | 7 | 13 | 27 | 4 | 15 | 14 | 34 | 14 | 39 | 46 | 51 | 42 |
| EPS in ₹ | 2.21 | 1.76 | 4.34 | 1.85 | 1.53 | 0.99 | 0.27 | 0.55 | 1.12 | 2.24 | 0.32 | 1.22 | 1.15 | 2.81 | 1.20 | 3.24 | 3.84 | 4.32 | 3.54 |
Medplus Health Services
Medplus Health Services
786.90
-12.25
(-1.53%)
Market Cap
9,565.30 Cr
EPS
12.57
PE Ratio
52.90
Dividend Yield
0.00 %
Industry
Retail52 Week High
1,045.30
52 Week Low
634.80
PB Ratio
5.42
Debt to Equity
0.64
Sector
Pharmacy Retail
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from6 analysts
Company News
View All News
Optival Health Solutions Private Limited, a subsidiary of MedPlus Health Services Limited, received a suspension order for its drug license at a store in Vishwakarma Nagar, Nagpur, Maharashtra. The Assistant Commissioner & Licensing Authority of Food & Drug Administration, Nagpur issued the 15-day suspension order under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company estimates a potential revenue loss of approximately Rs. 2.29 lakhs due to this suspension.
Optival Health Solutions Private Limited, a subsidiary of MedPlus Health Services Limited, received a seven-day suspension order for its Drug License for a store located on Kalyanadurgham Road in Andhra Pradesh. The suspension was issued by the Assistant Director, District Sales Licensing Authority, Drugs Control Administration, Ananthapuramu Zone-I under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The order was received on September 21, 2025, and is expected to result in a potential revenue loss of approximately Rs. 1.48 lakhs for the company.
MedPlus Subsidiary Faces Drug License Suspensions at Two Stores, Revenue Impact Rs 5.39 Lakhs
7 days ago
7 days agoOptival Health Solutions Private Limited, a subsidiary of MedPlus Health Services Limited, received suspension orders for drug licenses at two store locations. The Assistant Director of Drugs Control Administration in Karnataka suspended the license for three days at a store in Fort Main Road Old Hubli, resulting in potential revenue loss of Rs 0.79 lakhs. Additionally, the District Sales Licensing Authority in Andhra Pradesh suspended the license for ten days at a store in Venkataramana Colony Main Road, Kurnool District, with potential revenue loss of Rs 4.60 lakhs. Both suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The orders were received on September 18, 2025, with total potential revenue impact of approximately Rs 5.39 lakhs.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
786.90 | #1 9,565.30 | #2 52.90 | #1 6,184.70 | #2 9.18 | #1 150 | #1 195.80 | 35.50 | |
1,083.20 | 4,809.00 | #1 46.01 | 5,135.30 | #1 30.45 | 107 | 47.32 | 37.07 | |
41.00 | 60.20 | - | 9.20 | -4.17 | -2 | -166.67 | 54.63 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
9.18 %
Net Income Growth
128.96 %
Cash Flow Change
275.98 %
ROE
107.45 %
ROCE
49.93 %
EBITDA Margin (Avg.)
24.43 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 438 | 509 | 538 | 644 | 673 | 1,349 | 1,566 | 2,594 | 2,797 | 3,005 | 3,360 |
| Fixed Assets | 67 | 77 | 81 | 84 | 90 | 420 | 517 | 799 | 1,138 | 1,242 | 1,296 |
| Current Assets | 317 | 376 | 397 | 458 | 475 | 816 | 923 | 1,632 | 1,481 | 1,568 | 1,844 |
| Capital Work in Progress | 3 | 4 | 0 | 1 | 1 | 5 | 6 | 20 | 26 | 11 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 368 | 429 | 457 | 560 | 582 | 924 | 1,043 | 1,775 | 1,633 | 1,752 | 2,047 |
| Total Liabilities | 438 | 509 | 538 | 644 | 673 | 1,349 | 1,566 | 2,594 | 2,797 | 3,005 | 3,360 |
| Current Liabilities | 210 | 269 | 278 | 326 | 337 | 481 | 415 | 559 | 477 | 526 | 577 |
| Non Current Liabilities | 74 | 91 | 111 | 15 | 11 | 339 | 420 | 618 | 830 | 902 | 1,044 |
| Total Equity | 154 | 150 | 149 | 304 | 325 | 529 | 731 | 1,417 | 1,491 | 1,577 | 1,740 |
| Reserve & Surplus | 141 | 137 | 149 | 303 | 325 | 528 | 359 | 1,394 | 1,467 | 1,554 | 1,717 |
| Share Capital | 12 | 12 | 0 | 0 | 0 | 0 | 0 | 24 | 24 | 24 | 24 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 32 | -15 | -10 | 14 | 45 | 56 | -37 | -93 | 350 | -137 | -5 |
| Investing Activities | -16 | -32 | -15 | -18 | -19 | -28 | -35 | -703 | 429 | -83 | -318 |
| Operating Activities | -19 | -17 | 34 | 32 | 147 | -7 | 3 | 170 | 90 | 144 | 540 |
| Financing Activities | 67 | 35 | -29 | -1 | -83 | 90 | -6 | 440 | -170 | -198 | -228 |
Share Holding
| % Holding | Aug 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 96.68 % | 40.43 % | 40.43 % | 40.43 % | 40.43 % | 40.43 % | 40.43 % | 40.43 % | 40.41 % | 40.45 % | 40.39 % | 40.39 % | 40.39 % | 40.39 % | 40.34 % | 40.32 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 12.36 % | 0.00 % | 14.94 % | 14.85 % | 14.72 % | 15.23 % | 15.61 % | 16.42 % |
| DIIs | 0.00 % | 11.61 % | 11.99 % | 14.96 % | 14.31 % | 28.77 % | 28.16 % | 13.62 % | 25.49 % | 16.28 % | 22.47 % | 22.17 % | 27.97 % | 25.65 % | 26.19 % | 26.04 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 6.38 % | 5.83 % | 5.88 % | 6.22 % | 6.21 % | 6.13 % | 5.83 % | 6.40 % | 6.15 % | 7.30 % | 7.56 % | 11.84 % | 13.21 % | 13.10 % | 12.59 % |
| Others | 3.32 % | 41.58 % | 41.75 % | 38.73 % | 39.05 % | 24.59 % | 25.28 % | 40.12 % | 15.33 % | 37.12 % | 14.90 % | 15.03 % | 5.07 % | 5.52 % | 4.77 % | 4.64 % |
| No of Share Holders | 69 | 3,42,917 | 82,627 | 77,119 | 76,972 | 74,702 | 73,512 | 70,017 | 66,430 | 66,048 | 74,976 | 76,934 | 87,328 | 83,912 | 83,439 | 81,742 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 15 Dec 2023 |  Extraordinary General Meeting | NA | 15 Dec 2023 | 813.50 | 734.65 |
| 26 Sept 2024 |  Annual General Meeting | NA | 26 Sept 2024 | 682.10 | 689.45 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 650.80 | 674.95 |
| 31 Jan 2025 | Quarterly Result Announcement | NA | 31 Jan 2025 | 847.90 | 730.65 |
| 27 May 2025 | Quarterly Result Announcement | NA | 27 May 2025 | 732.15 | 977.00 |
| 02 Aug 2025 | Quarterly Result Announcement | NA | 02 Aug 2025 | 853.60 | 915.25 |
| 15 Sept 2025 | Annual General Meeting | NA | 15 Sept 2025 | 915.25 | 838.75 |
Announcements
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 20151 day ago
1 day agoClosure of Trading Window3 days ago
3 days agoUpdate Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 20154 days ago
4 days agoUpdate Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 20157 days ago
7 days agoUpdate Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 20158 days ago
8 days agoShareholder Meeting / Postal Ballot-Scrutinizers Report10 days ago
10 days agoShareholder Meeting / Postal Ballot-Outcome of AGMSep 15, 2025
Sep 15, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 10, 2025
Sep 10, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 09, 2025
Sep 09, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 05, 2025
Sep 05, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 04, 2025
Sep 04, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 23, 2025
Aug 23, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 23, 2025
Aug 23, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 22, 2025
Aug 22, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 21, 2025
Aug 21, 2025Reg. 34 (1) Annual Report.Aug 21, 2025
Aug 21, 2025Notice Of 19Th Annual General Meeting Of The Company For The Financial Year 2024-25Aug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 21, 2025
Aug 21, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 19, 2025
Aug 19, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 15, 2025
Aug 15, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Aug 14, 2025
Aug 14, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Aug 13, 2025
Aug 13, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Aug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 07, 2025
Aug 07, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Aug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 03, 2025
Aug 03, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 02, 2025
Aug 02, 2025Un-Audited Financial Results For The Quarter Ended June 30 2025Aug 02, 2025
Aug 02, 2025Board Meeting Outcome for Board Meeting Outcome For Meeting Held On August 02 2025Aug 02, 2025
Aug 02, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 02, 2025
Aug 02, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 31, 2025
Jul 31, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 28, 2025
Jul 28, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 26, 2025
Jul 26, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 23, 2025
Jul 23, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 22, 2025
Jul 22, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 19, 2025
Jul 19, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 18, 2025
Jul 18, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 16, 2025
Jul 16, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 15, 2025
Jul 15, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Jul 12, 2025
Jul 12, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 11, 2025
Jul 11, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And
Disclosure Requirements) Regulations 2015Jul 10, 2025
Jul 10, 2025Board Meeting Intimation for Consider & Approve Un-Audited Financial Result For Quarter Ended June 30 2025Jul 09, 2025
Jul 09, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And
Disclosure Requirements) Regulations 2015Jul 09, 2025
Jul 09, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Jul 08, 2025Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And
Disclosure Requirements) Regulations 2015Jul 08, 2025
Jul 08, 2025Technical Indicators
RSI(14)
Neutral 32.08
ATR(14)
Volatile 23.16
STOCH(9,6)
Neutral 23.79
STOCH RSI(14)
Oversold 12.57
MACD(12,26)
Bearish -4.35
ADX(14)
Weak Trend 20.49
UO(9)
Bearish 41.99
ROC(12)
Downtrend And Accelerating -5.31
WillR(14)
Oversold -88.29
Mutual Fund Holdings
SBI ELSS Tax Saver Fund Direct-Growth 
Invesco India Large & Mid Cap Fund Direct-Growth 
Tata India Innovation Fund Direct-Growth 
Bandhan Innovation Fund Direct-Growth 
Baroda BNP Paribas Health and Wellness Fund Direct-Growth 
Kotak Business Cycle Fund Direct - Growth 
Samco Multi Cap Fund Direct-Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
HDFC BSE 500 Index Fund Direct - Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
DSP Healthcare Fund Direct - Growth 
ICICI Prudential India Opportunities Fund Direct - Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
